サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1360316

細胞および遺伝子治療の製造品質管理（QC）市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日
ページ情報
英文 202 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
細胞および遺伝子治療の製造品質管理（QC）市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年
出版日: 2023年08月23日
発行: Transparency Market Research
ページ情報: 英文 202 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞および遺伝子治療の製造品質管理（QC）市場- レポートの範囲

世界の細胞および遺伝子治療の製造品質管理（QC）市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標に関する貴重な洞察を得る機会を研究しています。 このレポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの細胞および遺伝子治療の製造品質管理（QC）の世界市場の収益を掲載しています。また、2023年から2031年までの世界の細胞および遺伝子治療の製造品質管理（QC）市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、細胞および遺伝子治療の製造品質管理（QC）市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 3億7,170万米ドル
2031年の市場価値 28億米ドル
CAGR 24.6%

このレポートは、世界の細胞および遺伝子治療の製造品質管理（QC）市場の競合情勢を詳しく掘り下げています。世界の細胞および遺伝子治療の製造品質管理（QC）市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の細胞および遺伝子治療の製造品質管理（QC）市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界の細胞および遺伝子治療の製造品質管理（QC）市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • 技術の進歩
  • 主要な業界イベント
  • 地域/世界ごとの規制シナリオ
  • 関与する主な調査機関
  • COVID-19のパンデミックが業界に与える影響

第6章 世界の分析と予測：要素別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：要素別、2017-2031
    • 機器と付属品
    • 消耗品
    • その他
  • 市場魅力分析：要素別

第7章 世界の分析と予測：分析手法別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：分析手法別、2017-2031
    • 無菌試験
    • 純度試験
    • 効力試験
    • アイデンティティテスト
    • その他
  • 市場魅力分析：分析手法別

第8章 世界市場の分析と予測：プロセス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：プロセス別、2017-2031
    • 上流工程
    • 下流工程
    • プロセス開発
  • 市場魅力分析：プロセス別

第9章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2017-2031
    • 製薬およびバイオテクノロジー企業
    • 受託製造組織（CMO）
  • 市場魅力分析：エンドユーザー別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別、2022年
  • 企業プロファイル
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • QIAGEN
    • Charles River Laboratories International, Inc.
    • Lonza Group AG
    • Merck KGaA
    • Intertek Group plc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd.
図表

List of Tables

  • Table 01: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 02: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 03: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 04: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 07: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 08: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 09: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 10: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 12: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 13: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 14: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 17: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 18: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 19: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 20: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 23: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 24: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 25: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Component, 2017-2031
  • Table 28: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Analytical Method, 2017-2031
  • Table 29: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by Process, 2017-2031
  • Table 30: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Cell and Gene Therapy Manufacturing QC Market Value Share, by Component, 2022
  • Figure 03: Cell and Gene Therapy Manufacturing QC Market Value Share, by Product Type, 2022
  • Figure 04: Cell and Gene Therapy Manufacturing QC Market Value Share, by Process, 2022
  • Figure 05: Cell and Gene Therapy Manufacturing QC Market Value Share, by End-user, 2022
  • Figure 06: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 07: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component, 2023-2031
  • Figure 08: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Equipment & Accessories, 2017-2031
  • Figure 09: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Consumables, 2017-2031
  • Figure 10: Global Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn), by Others, 2017-2031
  • Figure 11: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 12: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 13: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Sterility Testing, 2017-2031
  • Figure 14: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Urological Surgery, 2017-2031
  • Figure 15: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Potency Testing, 2017-2031
  • Figure 16: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Identity Testing, 2017-2031
  • Figure 17: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 18: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 19: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Process, 2023-2031
  • Figure 20: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Upstream Processes, 2017-2031
  • Figure 21: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Downstream Processes, 2017-2031
  • Figure 22: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Process Development, 2017-2031
  • Figure 23: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 24: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 25: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 26: Global Cell and Gene Therapy Manufacturing QC Market Revenue (US$ Mn), by Contract Manufacturing Organizations (CMOs), 2017-31
  • Figure 27: Global Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 28: Global Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 29: North America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 31: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 32: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 33: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 34: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 35: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 36: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 37: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 38: North America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 39: North America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 40: Europe Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 44: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 45: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 46: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 47: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 48: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 49: Europe Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 50: Europe Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 51: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 55: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 56: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 57: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 58: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 59: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 60: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 61: Asia Pacific Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 62: Latin America Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 63: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 64: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 65: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 66: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 67: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 68: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 69: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 70: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 71: Latin America Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 72: Latin America Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 73: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 74: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 75: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 76: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Component, 2022 and 2031
  • Figure 77: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Component 2023-2031
  • Figure 78: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Analytical Method, 2022 and 2031
  • Figure 79: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by Analytical Method, 2023-2031
  • Figure 80: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by Process, 2022 and 2031
  • Figure 81: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, Process, 2023-2031
  • Figure 82: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 83: Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Attractiveness Analysis, by End-user, 2023-2031
目次
Product Code: TMRGL85805

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing quality control (QC) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing quality control (QC) market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing quality control (QC) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing quality control (QC) market.

Market Snapshot
Market Value in 2023US$ 371.7 Mn
Market Value in 2031US$ 2.8 Bn
CAGR24.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing quality control (QC) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing quality control (QC) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing quality control (QC) market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing quality control (QC) market. Key players operating in the global cell and gene therapy manufacturing quality control (QC) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing quality control (QC) market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Report:

  • What is the sales/revenue generated by cell and gene therapy manufacturing quality control (QC) across all regions during the forecast period?
  • What are the opportunities in the global cell and gene therapy manufacturing quality control (QC) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing quality control (QC) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing quality control (QC) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing quality control (QC) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. Major Research Institutes Involved
  • 5.5. COVID-19 Pandemic Impact on Industry

6. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Component

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Component, 2017-2031
    • 6.3.1. Equipment & Accessories
    • 6.3.2. Consumables
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Component

7. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Analytical Method

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 7.3.1. Sterility Testing
    • 7.3.2. Purity Testing
    • 7.3.3. Potency Testing
    • 7.3.4. Identity Testing
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Analytical Method

8. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Process

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Process, 2017-2031
    • 8.3.1. Upstream Processes
    • 8.3.2. Downstream Processes
    • 8.3.3. Process Development
  • 8.4. Market Attractiveness Analysis, by Process

9. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Pharmaceutical & Biotechnology Companies
    • 9.3.2. Contract Manufacturing Organizations (CMOs)
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Component, 2017-2031
    • 11.2.1. Equipment & Accessories
    • 11.2.2. Consumables
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 11.3.1. Sterility Testing
    • 11.3.2. Purity Testing
    • 11.3.3. Potency Testing
    • 11.3.4. Identity Testing
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Process, 2017-2031
    • 11.4.1. Upstream Processes
    • 11.4.2. Downstream Processes
    • 11.4.3. Process Development
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Pharmaceutical & Biotechnology Companies
    • 11.5.2. Contract Manufacturing Organizations (CMOs)
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Component
    • 11.7.2. By Analytical Method
    • 11.7.3. By Process
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Component, 2017-2031
    • 12.2.1. Equipment & Accessories
    • 12.2.2. Consumables
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 12.3.1. Sterility Testing
    • 12.3.2. Purity Testing
    • 12.3.3. Potency Testing
    • 12.3.4. Identity Testing
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Process, 2017-2031
    • 12.4.1. Upstream Processes
    • 12.4.2. Downstream Processes
    • 12.4.3. Process Development
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Pharmaceutical & Biotechnology Companies
    • 12.5.2. Contract Manufacturing Organizations (CMOs)
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Component
    • 12.7.2. By Analytical Method
    • 12.7.3. By Process
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Component, 2017-2031
    • 13.2.1. Equipment & Accessories
    • 13.2.2. Consumables
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 13.3.1. Sterility Testing
    • 13.3.2. Purity Testing
    • 13.3.3. Potency Testing
    • 13.3.4. Identity Testing
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Process, 2017-2031
    • 13.4.1. Upstream Processes
    • 13.4.2. Downstream Processes
    • 13.4.3. Process Development
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Pharmaceutical & Biotechnology Companies
    • 13.5.2. Contract Manufacturing Organizations (CMOs)
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Component
    • 13.7.2. By Analytical Method
    • 13.7.3. By Process
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Component, 2017-2031
    • 14.2.1. Equipment & Accessories
    • 14.2.2. Consumables
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 14.3.1. Sterility Testing
    • 14.3.2. Purity Testing
    • 14.3.3. Potency Testing
    • 14.3.4. Identity Testing
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Process, 2017-2031
    • 14.4.1. Upstream Processes
    • 14.4.2. Downstream Processes
    • 14.4.3. Process Development
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Pharmaceutical & Biotechnology Companies
    • 14.5.2. Contract Manufacturing Organizations (CMOs)
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Component
    • 14.7.2. By Analytical Method
    • 14.7.3. By Process
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Component, 2017-2031
    • 15.2.1. Equipment & Accessories
    • 15.2.2. Consumables
    • 15.2.3. Others
  • 15.3. Market Value Forecast, by Analytical Method, 2017-2031
    • 15.3.1. Sterility Testing
    • 15.3.2. Purity Testing
    • 15.3.3. Potency Testing
    • 15.3.4. Identity Testing
    • 15.3.5. Others
  • 15.4. Market Value Forecast, by Process , 2017-2031
    • 15.4.1. Upstream Processes
    • 15.4.2. Downstream Processes
    • 15.4.3. Process Development
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Pharmaceutical & Biotechnology Companies
    • 15.5.2. Contract Manufacturing Organizations (CMOs)
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Component
    • 15.7.2. By Analytical Method
    • 15.7.3. By Process
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. bioMerieux SA
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Bio-Rad Laboratories, Inc.
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. Bio-Techne Corporation
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. QIAGEN
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Charles River Laboratories International, Inc.
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Lonza Group AG
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Merck KGaA
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Intertek Group plc
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Thermo Fisher Scientific Inc.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Eurofins Scientific S.E.
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. F. Hoffmann-La Roche Ltd.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments